|
|
|
Insider
Information: |
Goeddel David V |
Relationship: |
10% Owner |
City: |
So. San Francisco |
State: |
CA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
9 |
|
Direct
Shares |
21,008,913 |
|
Indirect Shares
|
32,725,451 |
|
|
Direct
Value |
$109,933,645 |
|
|
Indirect Value
|
$151,903,676 |
|
|
Total
Shares |
53,734,364 |
|
|
Total
Value |
$261,837,321 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
63
|
4
|
Stock
price went up :
|
24
|
1
|
Stock
price went down : |
39
|
3
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
-0.2%
|
-73.3%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Immune Design Corp. |
IMDZ |
10% Owner |
2016-09-20 |
3,961,942 |
2014-07-29 |
0 |
Premium* |
|
Gritstone Oncology, Inc. |
GRTS |
Managing Partner |
2018-10-02 |
3,102,934 |
2018-10-02 |
0 |
Premium* |
|
Ngm Biopharmaceuticals Inc |
NGM |
Director, 10% Owner |
2024-04-05 |
0 |
2024-04-05 |
1,000 |
Premium* |
|
Rapt Therapeutics, Inc. |
RAPT |
Managing Partner, 10% ... |
2020-09-22 |
5,630,497 |
2019-11-04 |
195,401 |
Premium* |
|
Oric Pharmaceuticals, Inc. |
ORIC |
Managing Partner, 10% ... |
2020-04-28 |
4,768,181 |
|
0 |
Premium* |
|
Revolution Medicines, Inc. |
RVMD |
10% Owner |
2020-11-16 |
2,151,026 |
2020-11-16 |
3,799,202 |
Premium* |
|
Nurix Therapeutics, Inc. |
NRIX |
10% Owner |
2021-05-05 |
1,394,333 |
2021-05-05 |
1,420,954 |
Premium* |
|
Tenaya Therapeutics, Inc. |
TNYA |
|
2021-08-03 |
0 |
2024-02-12 |
22,999,565 |
Premium* |
|
Effector Therapeutics Ord Shs |
EFTR |
10% Owner |
|
0 |
2021-08-25 |
4,309,329 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
145 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 5 of 6
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2022-05-11 |
4 |
B |
$11.23 |
$935,354 |
I/I |
83,175 |
34,563 |
2.25 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2022-05-12 |
4 |
B |
$11.62 |
$966,678 |
I/I |
83,175 |
37,308 |
2.25 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2022-05-17 |
4 |
B |
$13.42 |
$1,194,779 |
I/I |
89,049 |
45,610 |
2.25 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2022-06-01 |
4 |
B |
$13.45 |
$1,237,400 |
I/I |
92,000 |
56,836 |
2.25 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2023-01-10 |
4 |
B |
$4.84 |
$484,519 |
I/I |
100,070 |
480,542 |
2.25 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2022-11-03 |
4 |
B |
$4.99 |
$519,107 |
I/I |
104,090 |
304,787 |
2.25 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2020-04-08 |
4 |
B |
$14.95 |
$1,683,400 |
I/I |
112,602 |
17,896,978 |
2.25 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2020-03-31 |
4 |
B |
$12.53 |
$1,479,380 |
I/I |
118,067 |
17,513,144 |
2.25 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2020-04-01 |
4 |
B |
$12.26 |
$1,447,501 |
I/I |
118,067 |
17,631,211 |
2.25 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2020-04-07 |
4 |
B |
$14.38 |
$1,779,209 |
I/I |
123,728 |
17,784,376 |
2.25 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2020-03-24 |
4 |
B |
$12.22 |
$1,568,767 |
I/I |
128,377 |
17,392,661 |
2.25 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2022-05-13 |
4 |
B |
$0.00 |
$0 |
I/I |
129,365 |
41,577 |
2.17 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2024-04-05 |
4 |
D |
$0.00 |
$0 |
D/D |
(134,180) |
0 |
0 |
- |
|
TNYA |
Tenaya Therapeutics, Inc. |
Director |
|
2023-01-18 |
4 |
B |
$2.52 |
$341,432 |
I/I |
135,688 |
9,800,535 |
2.25 |
- |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2020-03-20 |
4 |
B |
$11.77 |
$1,684,075 |
I/I |
143,082 |
17,093,897 |
2.25 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2020-03-19 |
4 |
B |
$11.59 |
$1,720,698 |
I/I |
148,464 |
16,950,815 |
2.25 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2020-03-23 |
4 |
B |
$11.63 |
$1,981,601 |
I/I |
170,387 |
17,264,284 |
2.25 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2023-01-31 |
4 |
B |
$5.00 |
$883,403 |
I/I |
176,730 |
927,231 |
2.25 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2023-01-11 |
4 |
B |
$4.76 |
$994,840 |
I/I |
209,000 |
689,542 |
2.25 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2019-08-07 |
4 |
B |
$14.00 |
$3,143,000 |
I/I |
224,500 |
16,356,743 |
2.25 |
- |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2022-01-24 |
4 |
B |
$0.00 |
$0 |
I/I |
250,000 |
8,250 |
2.17 |
% |
|
IMDZ |
Immune Design Corp. |
10% Owner |
|
2014-07-29 |
4 |
B |
$12.00 |
$4,788,192 |
D/D |
399,016 |
3,161,942 |
2.45 |
- |
|
RAPT |
Rapt Therapeutics, Inc. |
Managing Partner |
|
2020-08-17 |
4 |
S |
$22.75 |
$12,254,379 |
D/D |
(538,654) |
4,443,679 |
0 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2022-01-25 |
4 |
B |
$0.00 |
$0 |
I/I |
599,701 |
28,041 |
2.17 |
% |
|
RAPT |
Rapt Therapeutics, Inc. |
Managing Partner |
|
2020-09-22 |
4 |
S |
$30.85 |
$18,756,800 |
D/D |
(608,000) |
3,835,679 |
0 |
% |
|
145 Records found
|
|
Page 5 of 6 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|